• Type: Second generation cephalosporin
  • Dosage Forms: capsule, tablet, oral suspension
  • Dosage Strengths: capsule: 250mg, 500mg; tablet 500mg; oral suspension: 125mg/5mL, 250mg/5mL, 375mg/5mL
  • Routes of Administration: PO
  • Common Trade Names: Ceclor, Raniclor

Adult Dosing

Infection, bacterial

  • Immediate-release:
    • 250-500 mg PO q8h
      • Max: 2 g/day
  • Extended-release:
    • 500 mg ER PO q12h
      • Max 2 g/day

Pediatric Dosing

Infection, bacterial

  • 1+ mo
    • 20-40 mg/kg/day PO divided 18-12h
      • Max: 1 g/day

Special Populations

  • Pregnancy Rating: B
  • Lactation: May use while breastfeeding
  • Renal Dosing
    • Adult:
      • No adjustment
      • HD: Give dose after dialysis
      • PD: No supplement
    • Pediatric
      • CrCl <10: Decrease dose 50%
      • HD: Give dose after dialysis
    • PD: No supplement
  • Hepatic Dosing
    • Adult:
      • Not defined
    • Pediatric
      • Not defined


  • Allergy to class/drug
  • Caution:
    • Hypersensitivity to penicillin
    • Renal impairment
    • Concurrent nephrotoxic agent
    • Seizure disorder
    • Recent abx-associated colitis history

Adverse Reactions




  • Half-life: 35-54 min; 2-3hr in ERSD
  • Metabolism: Partial, hepatic
  • Excretion: Urine primarily (60-85% unchanged)
  • Mechanism of Action: Inhibits cell wall mucopeptide synthesis; bactericidal

Antibiotic Sensitivities[1]

Group Organism Sensitivity
Gram PositiveStrep. Group A, B, C, GS
Strep. PneumoniaeS
Viridans strepS
Strep. anginosus gpX1
Enterococcus faecalisR
Enterococcus faeciumX1
Staph. EpidermidisI
C. jeikeiumR
L. monocytogenesR
Gram NegativesN. gonorrhoeaeI
N. meningitidisI
Moraxella catarrhalisI
H. influenzaeS
E. coliS
Klebsiella spS
E. coli/Klebsiella ESBL+R
E coli/Klebsiella KPC+R
Enterobacter sp, AmpC negR
Enterobacter sp, AmpC posR
Serratia spR
Serratia marcescensX1
Salmonella spX1
Shigella spX1
Proteus mirabilisS
Proteus vulgarisR
Providencia sp.R
Morganella sp.R
Citrobacter freundiiR
Citrobacter diversusR
Citrobacter sp.I
Aeromonas spX1
Acinetobacter sp.R
Pseudomonas aeruginosaR
Burkholderia cepaciaR
Stenotrophomonas maltophiliaR
Yersinia enterocoliticaX1
Francisella tularensisX1
Brucella sp.X1
Legionella sp.R
Pasteurella multocidaX1
Haemophilus ducreyiX1
Vibrio vulnificusX1
MiscChlamydophila spX1
Mycoplasm pneumoniaeX1
Rickettsia spX1
Mycobacterium aviumX1
Bacteroides fragilisR
Prevotella melaninogenicaS
Clostridium difficileX1
Clostridium (not difficile)X1
Fusobacterium necrophorumX1
Peptostreptococcus sp.S


  • S susceptible/sensitive (usually)
  • I intermediate (variably susceptible/resistant)
  • R resistant (or not effective clinically)
  • S+ synergistic with cell wall antibiotics
  • U sensitive for UTI only (non systemic infection)
  • X1 no data
  • X2 active in vitro, but not used clinically
  • X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
  • X4 active in vitro, but not clinically effective for strep pneumonia

See Also


  • Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. J Pediatr. 2001;139(2):317-319. [PubMed 11487763]
  • American Thoracic Society, “Guidelines for the Initial Management of Adults With Community-Acquired Pneumonia: Diagnosis, Assessment of Severity, and Initial Antimicrobial Therapy,” Am Rev Respir Dis, 1993, 148(5):1418-26. [PubMed 8239186]
  • Aronoff GR, Bennett WM, Berns JS, et al, Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children, 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 61, 153.
  • Boguniewicz M and Leung DYM, “Hypersensitivity Reactions to Antibiotics Commonly Used in Children,” Pediatr Infect Dis J, 1995, 14(3):221-31. [PubMed 7761188]
  • Campagna JD, Bond MC, Schabelman E, Hayes BD. The use of cephalosporins in penicillin-allergic patients: a literature review. J Emerg Med. 2012; 42(5):612-620. [PubMed 21742459]
  • Cefaclor Capsules [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals; July 2015.
  • Cefaclor Extended-Release Tablets [prescribing information]. North Wales, PA: Teva Pharmaceuticals; December 2014.
  1. Sanford Guide to Antimicrobial Therapy 2014
This article is issued from Wikem. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.